<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03267251</url>
  </required_header>
  <id_info>
    <org_study_id>UNewMexico</org_study_id>
    <nct_id>NCT03267251</nct_id>
  </id_info>
  <brief_title>Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV)</brief_title>
  <acronym>EPICC-HPV</acronym>
  <official_title>Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klein Buendel, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination against Human Papillomavirus is recommended for adolescent females by the&#xD;
      Advisory Committee on Immunization Practices (ACIP), physicians, and many medical&#xD;
      organizations, yet uptake of HPV vaccines remains very low. CDC data reveal that in 2013 only&#xD;
      44.3% of 13-17 year old females in New Mexico (and 37.6% nationwide) had completed the 3-dose&#xD;
      HPV vaccine series. These data reveal the uptake of the HPV vaccines is unacceptably low,&#xD;
      thereby diminishing its ability to provide population-level protection against the HPV types&#xD;
      known to cause cervical, vaginal, and vulvar cancers in women, oropharyngeal and anal cancers&#xD;
      in men and women, and penile cancers in men. The danger of very low vaccination rates is that&#xD;
      adolescents of all ages will continue to be vulnerable to HPV and the associated cancer&#xD;
      risks.&#xD;
&#xD;
      Despite recommendations for HPV, parents continue to have concerns about HPV vaccination.&#xD;
      Clinicians often lack a clear frame for discussions about HPV vaccination with parents, so&#xD;
      much so that recent research indicates that pediatricians' discussions with parents about&#xD;
      vaccinations in general often take the form of bargaining, e.g., &quot;since this may be too early&#xD;
      for the vaccination, can we delay the vaccination schedule?&quot; Effective messaging is needed to&#xD;
      close a knowledge gap among parents around HPV and HPV vaccines, improve communication and&#xD;
      shared decision-making about HPV vaccination between adolescent girls' parents and&#xD;
      physicians, and ultimately prompt uptake of HPV vaccines.&#xD;
&#xD;
      This project will employ a web-based intervention on HPV as a way to improve knowledge,&#xD;
      communication and shared decision-making about HPV vaccination for 11-13 year old girls and&#xD;
      their parents. A clinic-based comparative effectiveness randomized trial will be used to&#xD;
      examine the impact of the website on vaccine-related outcomes and vaccine uptake. New Mexico&#xD;
      pediatric clinics will be randomly assigned to either the usual care clinic-based&#xD;
      communication about HPV vaccination or to usual care plus web-based dissemination.&#xD;
      Assessments of vaccine-related outcomes, including shared decision-making between girls,&#xD;
      parents and physicians, will be assessed at baseline, 3 months, and 9 months and vaccine&#xD;
      uptake and dose adherence will be abstracted from clinic vaccine records at 9 months. An&#xD;
      effective web-based resource should increase parents' knowledge, intentions and motivations&#xD;
      to vaccinate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uptake of the Human Papillomavirus (HPV) vaccines in the U.S. remains very low. (RQ-1) The&#xD;
      quadrivalent HPV vaccine has been routinely recommended for adolescent females by the&#xD;
      Advisory Committee on Immunization Practices. The Centers for Disease Control and Prevention&#xD;
      (CDC) reports that in 2013, the uptake of HPV vaccines (all three doses) was 37.6% for&#xD;
      females (ages 13-17 years). The Healthy People 2020 target for vaccination coverage of&#xD;
      adolescent females aged 13-15 years is 80.0% for ≥3 doses of HPV, far above current national&#xD;
      rates for HPV vaccine uptake. In New Mexico, the 3-dose completion rate for HPV vaccination&#xD;
      for females ages 13-17 is currently 44.3%. However, for girls in the recommended early age&#xD;
      vaccination range (11-13), a recent estimate provided by the New Mexico Dept. of Public&#xD;
      Health Vaccination Program reveals that in 2012 approximately 7% of 11-12 year old New Mexico&#xD;
      adolescent girls completed all 3 doses of HPV vaccine, and in 2013 approximately 9% had&#xD;
      completed all 3 doses. In the simplest terms, the uptake of the HPV vaccines is unacceptably&#xD;
      low, diminishing its ability to confer population-level protection against the HPV types&#xD;
      known to cause cervical, vaginal, and vulvar cancers in women, oropharyngeal and anal cancers&#xD;
      in men and women, and penile cancers in men. The danger given the very low vaccination rates&#xD;
      reported above is that a significant proportion of adolescents of all ages will not receive&#xD;
      the HPV vaccine and continue to be vulnerable to HPV and the associated cancer risks.&#xD;
&#xD;
      Physicians' views of and recommendations for HPV vaccination and parents' perceptions of the&#xD;
      HPV vaccines predict HPV vaccine uptake. Despite convincing data on the safety and&#xD;
      effectiveness of the vaccines, and a wide variety of medical organizations recommending them,&#xD;
      parents continue to have concerns about HPV vaccination. The pattern of vaccine uptake also&#xD;
      increases the risk of vaccine-related health disparity across gender and ethnic groups. While&#xD;
      minority youth are more likely to begin vaccination programs, they are significantly less&#xD;
      likely to complete vaccination programs for reasons that remain in debate. As a result,&#xD;
      minority youth lack adequate protection from preventable illnesses. This is particularly&#xD;
      problematic as such deficits can build into larger medical consequences later in life.&#xD;
&#xD;
      Diffusion of Innovations theory (DI) provides a framework for explaining vaccine uptake. DI&#xD;
      is a theory that seeks to explain how, what, and why new ideas (e.g., vaccines) are spread&#xD;
      through different populations at different rates. One tenet of DI is that effective messaging&#xD;
      is necessary for the diffusion of a new innovation, and there is a lack of effective&#xD;
      messaging to parents to close the knowledge gap about HPV vaccines, resulting in poor uptake.&#xD;
      Both the CDC and the President's Cancer Advisory Board call for the development of effective&#xD;
      and accessible messaging to improve decision-making around adolescent vaccination,&#xD;
      particularly for the HPV vaccines. Effective messaging is especially important to reach&#xD;
      minority groups who experience health disparities, especially to parents for whom English may&#xD;
      not be the first language. Because parents drive the decision-making around vaccine uptake,&#xD;
      messaging should be focused on them, but should include adolescents as well. Clinicians also&#xD;
      often lack a clear frame for discussions about HPV vaccination with parents. The topic of&#xD;
      vaccines is a polarizing one for many physicians and their patients (parents and children).&#xD;
      Physicians often find their expertise and recommendations being accepted by parents for&#xD;
      certain areas of their child's care (e.g., diet, seatbelt use), but not others. Providers are&#xD;
      using many strategies in response, but think few are effective. Very little research has been&#xD;
      conducted on clinic interventions that improve vaccine uptake, or on interventions that would&#xD;
      help physicians effectively frame HPV vaccination discussion with parents. With the recent&#xD;
      approval of the new 9-valent vaccine (Gardasil 9), a further premium is placed on effective&#xD;
      communication between parents and physicians communicating about HPV vaccines. The focus in&#xD;
      this project is to employ a developed and efficacious digital intervention on HPV messaging&#xD;
      (GoHealthyGirls.org) as a way to improve the communication and shared decision-making about&#xD;
      HPV vaccination between girls' parents and pediatricians. An effective web-based resource in&#xD;
      pediatric and family practice clinics should increase parents' knowledge, intentions and&#xD;
      motivations to vaccinate, enhance pediatrician-parent shared decision making for HPV&#xD;
      vaccination, and increase HPV vaccination rates.&#xD;
&#xD;
      A clinic-based comparative effectiveness randomized trial will be used to examine the impact&#xD;
      of the GoHealthyGirls website on vaccine-related outcomes and vaccine uptake. Pediatric&#xD;
      clinics within established health care networks in New Mexico will be randomly assigned to&#xD;
      either the usual care clinic-based communication about HPV vaccination (UC) or to usual care&#xD;
      plus web-based dissemination (UC+GHG). Assessments of vaccine-related outcomes, including&#xD;
      shared decision making between parents and physicians, will be assessed at baseline, 3&#xD;
      months, and 9 months. Vaccine uptake and dose adherence will be abstracted from clinic&#xD;
      vaccine records. Comparative effectiveness, sensitivity analysis, and heterogeneity of&#xD;
      treatment effects analyses are planned. An extensive parent and stakeholder engagement plan&#xD;
      will be utilized, and includes an Adolescent HPV Immunization Advocacy Coalition that will&#xD;
      involve parents across New Mexico, and an Adolescent HPV Immunization Expert Advisory Board&#xD;
      that will involve clinicians, vaccine experts and researchers in New Mexico. Quarterly&#xD;
      meetings of these groups will review project plans, protocols, and processes, and link the&#xD;
      project to the communities and population of New Mexico.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Parallel record under the prime awardee (Klein Buendel)&#xD;
  </why_stopped>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This research project will compare usual care clinic-based communication about HPV vaccination (UC) to usual care plus web-based dissemination (UC+GHG) of information on HPV vaccination to parents and adolescent girls using a pair-matched group-randomized pretest-posttest design protocol. Pediatric/family practice clinics in New Mexico (n=30 clinics) will be pair-mated and one clinic per pair will be randomized to UC+GHG condition via the website, GoHealthyGirls.org. The remaining clinic will continue to receive UC only. Assessment protocols will be conducted at pretest, 3-month follow-up, and 9-month follow-up points, measuring knowledge, compatibility and relative advantage principles in DI, shared decision making, and vaccine adoption by girls. Thus, the proposed trial design will be a 2 (UC v. UC+GHG) intervention x 3 (level of time - pretest vs. 3-month follow-up vs. 9-month follow-up) mixed factorial design with participants nested within clinics.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Adoption</measure>
    <time_frame>9-month follow up</time_frame>
    <description>Shot records of initial and second HPV vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parental HPV vaccination knowledge - questionnaire</measure>
    <time_frame>Baseline, 3-month and 9-month follow-up</time_frame>
    <description>Assessment of HPV-related knowledge among parents, developed by Perez, et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shared decision-making (SDM-Q9) questionnaire</measure>
    <time_frame>3-month and 9-month follow-up</time_frame>
    <description>Assessment of Shared Decision Making, developed by Kriston, et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician-Patient Communication questionnaire</measure>
    <time_frame>3-month and 9-month follow-up</time_frame>
    <description>Satisfaction of communication between healthcare provider and parent, developed by Street, et al.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vaccine Decision Making</condition>
  <arm_group>
    <arm_group_label>Usual Clinic communication - HPV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Usual and Customary HPV Information - CDC pamphlet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care and Web App on HPV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vacteens Web app for mobile devices</intervention_name>
    <description>The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.</description>
    <arm_group_label>Usual Care and Web App on HPV Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Usual and Customary HPV Information - CDC pamphlet</intervention_name>
    <description>The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.</description>
    <arm_group_label>Usual Clinic communication - HPV Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parent of an adolescent girl ages 11-14, adolescent girl has not yet received HPV&#xD;
             vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  adolescent girl has received HPV vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Lawrence, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Patient Centered Outcomes Research Organization</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>July 10, 2023</last_update_submitted>
  <last_update_submitted_qc>July 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine Decision Making</keyword>
  <keyword>Public Health</keyword>
  <keyword>Health Communication</keyword>
  <keyword>Digital Interventions</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03267251
org study id: UNewMexico
nct id: NCT03267251
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Vaccination against Human Papillomavirus is recommended for adolescent females by the
      Advisory Committee on Immunization Practices (ACIP), physicians, and many medical
      organizations, yet uptake of HPV vaccines remains very low. CDC data reveal that in 2013 only
      44.3% of 13-17 year old females in New Mexico (and 37.6% nationwide) had completed the 3-dose
      HPV vaccine series. These data reveal the uptake of the HPV vaccines is unacceptably low,
      thereby diminishing its ability to provide population-level protection against the HPV types
      known to cause cervical, vaginal, and vulvar cancers in women, oropharyngeal and anal cancers
      in men and women, and penile cancers in men. The danger of very low vaccination rates is that
      adolescents of all ages will continue to be vulnerable to HPV and the associated cancer
      risks.

      Despite recommendations for HPV, parents continue to have concerns about HPV vaccination.
      Clinicians often lack a clear frame for discussions about HPV vaccination with parents, so
      much so that recent research indicates that pediatricians' discussions with parents about
      vaccinations in general often take the form of bargaining, e.g., "since this may be too early
      for the vaccination, can we delay the vaccination schedule?" Effective messaging is needed to
      close a knowledge gap among parents around HPV and HPV vaccines, improve communication and
      shared decision-making about HPV vaccination between adolescent girls' parents and
      physicians, and ultimately prompt uptake of HPV vaccines.

      This project will employ a web-based intervention on HPV as a way to improve knowledge,
      communication and shared decision-making about HPV vaccination for 11-13 year old girls and
      their parents. A clinic-based comparative effectiveness randomized trial will be used to
      examine the impact of the website on vaccine-related outcomes and vaccine uptake. New Mexico
      pediatric clinics will be randomly assigned to either the usual care clinic-based
      communication about HPV vaccination or to usual care plus web-based dissemination.
      Assessments of vaccine-related outcomes, including shared decision-making between girls,
      parents and physicians, will be assessed at baseline, 3 months, and 9 months and vaccine
      uptake and dose adherence will be abstracted from clinic vaccine records at 9 months. An
      effective web-based resource should increase parents' knowledge, intentions and motivations
      to vaccinate
Uptake of the Human Papillomavirus (HPV) vaccines in the U.S. remains very low. (RQ-1) The
      quadrivalent HPV vaccine has been routinely recommended for adolescent females by the
      Advisory Committee on Immunization Practices. The Centers for Disease Control and Prevention
      (CDC) reports that in 2013, the uptake of HPV vaccines (all three doses) was 37.6% for
      females (ages 13-17 years). The Healthy People 2020 target for vaccination coverage of
      adolescent females aged 13-15 years is 80.0% for ≥3 doses of HPV, far above current national
      rates for HPV vaccine uptake. In New Mexico, the 3-dose completion rate for HPV vaccination
      for females ages 13-17 is currently 44.3%. However, for girls in the recommended early age
      vaccination range (11-13), a recent estimate provided by the New Mexico Dept. of Public
      Health Vaccination Program reveals that in 2012 approximately 7% of 11-12 year old New Mexico
      adolescent girls completed all 3 doses of HPV vaccine, and in 2013 approximately 9% had
      completed all 3 doses. In the simplest terms, the uptake of the HPV vaccines is unacceptably
      low, diminishing its ability to confer population-level protection against the HPV types
      known to cause cervical, vaginal, and vulvar cancers in women, oropharyngeal and anal cancers
      in men and women, and penile cancers in men. The danger given the very low vaccination rates
      reported above is that a significant proportion of adolescents of all ages will not receive
      the HPV vaccine and continue to be vulnerable to HPV and the associated cancer risks.

      Physicians' views of and recommendations for HPV vaccination and parents' perceptions of the
      HPV vaccines predict HPV vaccine uptake. Despite convincing data on the safety and
      effectiveness of the vaccines, and a wide variety of medical organizations recommending them,
      parents continue to have concerns about HPV vaccination. The pattern of vaccine uptake also
      increases the risk of vaccine-related health disparity across gender and ethnic groups. While
      minority youth are more likely to begin vaccination programs, they are significantly less
      likely to complete vaccination programs for reasons that remain in debate. As a result,
      minority youth lack adequate protection from preventable illnesses. This is particularly
      problematic as such deficits can build into larger medical consequences later in life.

      Diffusion of Innovations theory (DI) provides a framework for explaining vaccine uptake. DI
      is a theory that seeks to explain how, what, and why new ideas (e.g., vaccines) are spread
      through different populations at different rates. One tenet of DI is that effective messaging
      is necessary for the diffusion of a new innovation, and there is a lack of effective
      messaging to parents to close the knowledge gap about HPV vaccines, resulting in poor uptake.
      Both the CDC and the President's Cancer Advisory Board call for the development of effective
      and accessible messaging to improve decision-making around adolescent vaccination,
      particularly for the HPV vaccines. Effective messaging is especially important to reach
      minority groups who experience health disparities, especially to parents for whom English may
      not be the first language. Because parents drive the decision-making around vaccine uptake,
      messaging should be focused on them, but should include adolescents as well. Clinicians also
      often lack a clear frame for discussions about HPV vaccination with parents. The topic of
      vaccines is a polarizing one for many physicians and their patients (parents and children).
      Physicians often find their expertise and recommendations being accepted by parents for
      certain areas of their child's care (e.g., diet, seatbelt use), but not others. Providers are
      using many strategies in response, but think few are effective. Very little research has been
      conducted on clinic interventions that improve vaccine uptake, or on interventions that would
      help physicians effectively frame HPV vaccination discussion with parents. With the recent
      approval of the new 9-valent vaccine (Gardasil 9), a further premium is placed on effective
      communication between parents and physicians communicating about HPV vaccines. The focus in
      this project is to employ a developed and efficacious digital intervention on HPV messaging
      (GoHealthyGirls.org) as a way to improve the communication and shared decision-making about
      HPV vaccination between girls' parents and pediatricians. An effective web-based resource in
      pediatric and family practice clinics should increase parents' knowledge, intentions and
      motivations to vaccinate, enhance pediatrician-parent shared decision making for HPV
      vaccination, and increase HPV vaccination rates.

      A clinic-based comparative effectiveness randomized trial will be used to examine the impact
      of the GoHealthyGirls website on vaccine-related outcomes and vaccine uptake. Pediatric
      clinics within established health care networks in New Mexico will be randomly assigned to
      either the usual care clinic-based communication about HPV vaccination (UC) or to usual care
      plus web-based dissemination (UC+GHG). Assessments of vaccine-related outcomes, including
      shared decision making between parents and physicians, will be assessed at baseline, 3
      months, and 9 months. Vaccine uptake and dose adherence will be abstracted from clinic
      vaccine records. Comparative effectiveness, sensitivity analysis, and heterogeneity of
      treatment effects analyses are planned. An extensive parent and stakeholder engagement plan
      will be utilized, and includes an Adolescent HPV Immunization Advocacy Coalition that will
      involve parents across New Mexico, and an Adolescent HPV Immunization Expert Advisory Board
      that will involve clinicians, vaccine experts and researchers in New Mexico. Quarterly
      meetings of these groups will review project plans, protocols, and processes, and link the
      project to the communities and population of New Mexico.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: This research project will compare usual care clinic-based communication about HPV vaccination (UC) to usual care plus web-based dissemination (UC+GHG) of information on HPV vaccination to parents and adolescent girls using a pair-matched group-randomized pretest-posttest design protocol. Pediatric/family practice clinics in New Mexico (n=30 clinics) will be pair-mated and one clinic per pair will be randomized to UC+GHG condition via the website, GoHealthyGirls.org. The remaining clinic will continue to receive UC only. Assessment protocols will be conducted at pretest, 3-month follow-up, and 9-month follow-up points, measuring knowledge, compatibility and relative advantage principles in DI, shared decision making, and vaccine adoption by girls. Thus, the proposed trial design will be a 2 (UC v. UC+GHG) intervention x 3 (level of time - pretest vs. 3-month follow-up vs. 9-month follow-up) mixed factorial design with participants nested within clinics.
primary purpose: Prevention
masking: None (Open Label)
measure: Vaccine Adoption
time frame: 9-month follow up
description: Shot records of initial and second HPV vaccination
measure: Parental HPV vaccination knowledge - questionnaire
time frame: Baseline, 3-month and 9-month follow-up
description: Assessment of HPV-related knowledge among parents, developed by Perez, et al.
measure: Shared decision-making (SDM-Q9) questionnaire
time frame: 3-month and 9-month follow-up
description: Assessment of Shared Decision Making, developed by Kriston, et al.
measure: Physician-Patient Communication questionnaire
time frame: 3-month and 9-month follow-up
description: Satisfaction of communication between healthcare provider and parent, developed by Street, et al.
arm group label: Usual Clinic communication - HPV Vaccine
arm group type: Active Comparator
description: Standard Usual and Customary HPV Information - CDC pamphlet
arm group label: Usual Care and Web App on HPV Vaccine
arm group type: Experimental
description: Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
intervention type: Other
intervention name: Vacteens Web app for mobile devices
description: The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
arm group label: Usual Care and Web App on HPV Vaccine
intervention type: Other
intervention name: Standard Usual and Customary HPV Information - CDC pamphlet
description: The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
arm group label: Usual Clinic communication - HPV Vaccine
criteria: 
gender: All
minimum age: 26 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: William Lawrence, MD
role: Study Chair
affiliation: Patient Centered Outcomes Research Organization
responsible party type: Sponsor
sharing ipd: No
ipd description: No plan at this time.